Icosavax’s $209.3 Million IPO

Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal.

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, closed its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, were $209.3 million. Icosavax’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “ICVX.”

Jefferies, Cowen, Evercore ISI and William Blair acted as joint book-running managers for the offering.

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.

The Wilmer Hale team representing the underwriters consisted of Partner Lisa Firenze (Picture), Counsel Jeffries Oliver-Li and Associate Gerard Fischetti, with support from Partners Bruce Manheim and Colleen Superko and Attorney Heidi Treiber.

Latham & Watkins LLP represented Icosavax in the offering with a corporate deal team led by San Diego partners Cheston Larson and Matt Bush, with associates Alaina Ellis, Julian Brody, Shelby Harrison. Advice was also provided on benefits and compensation matters by San Diego partner Holly Bauer, with Los Angeles associate Vanessa King; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associates Chad Jennings, Margaret Rote and San Diego associate Kiera Murphy; on intellectual property matters by Bay Area/San Diego partner Chris Hazuka, with San Diego associates Robert Yeh and Mike Sweeney; on data privacy matters by Bay Area counsel Heather Deixler; and on tax matters by Century City partner Sam Weiner, with Los Angeles associate Brian Rogers.

Involved fees earner: Holly Bauer – Latham & Watkins; Julian Brody – Latham & Watkins; Matthew Bush – Latham & Watkins; Heather Deixler – Latham & Watkins; Alaina Ellis – Latham & Watkins; Shelby Harrison – Latham & Watkins; Christopher Hazuka – Latham & Watkins; Chad Jennings – Latham & Watkins; Vanessa King – Latham & Watkins; Cheston Larson – Latham & Watkins; Kiera Murphy – Latham & Watkins; Betty Pang – Latham & Watkins; Elizabeth Richards – Latham & Watkins; Brian Rogers – Latham & Watkins; Margaret Rote – Latham & Watkins; Michael Sweeney – Latham & Watkins; Samuel Weiner – Latham & Watkins; Robert Yeh – Latham & Watkins; Lisa Firenze – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Gerard Fischetti – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Bruce Manheim Jr – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Jeffries Oliver-Li – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Colleen Superko – WilmerHaleWilmer Cutler Pickering Hale and Dorr; Heidi Treiber – WilmerHaleWilmer Cutler Pickering Hale and Dorr;

Law Firms: Latham & Watkins; WilmerHaleWilmer Cutler Pickering Hale and Dorr;

Clients: Cowen Inc.; Evercore Inc.; Icosavax; Jefferies; William Blair & Company, L.L.C.;

Author: Martina Bellini